UNSPSC 51372801: Ketazocine

This classification denotes an opioid receptor agonist with the molecular formula C18H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6IO4IG518S, chemically known as 2,6-methano-3-benzazocin-1(2h)-one, 3-(cyclopropylmethyl)-3,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-, (2alpha,6alpha,11s*)- but generally known as ketazocine, which bears US NIH Compound Identifier 71426. European Medicines Agency schedules Ketazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08367MIG.

UNSPSC 51372801 Ketazocine is a Commodity code that in practice captures state and local procurement of pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter products — though the recent solicitations show limited activity directly under this specific code and instead reflect broader pharmaceutical supply agreements. State and local health authorities, cooperative purchasing alliances, and health and human services commissions are the primary issuing bodies soliciting under or tangentially to this code. The work ranges from direct purchase of emergency medical countermeasures (naloxone and drug deactivation systems) to participation in multi-state cooperative purchasing frameworks for generic pharmaceuticals and OTC inventory to exploratory market research for direct-to-manufacturer prescription programs. Vendors must typically comply with FDA requirements, cGMP and Drug Supply Chain Security Act certifications, drug-free workplace and E-Verify attestations, and substantial insurance coverage (commercial general liability in the $2 million to $5 million range, network security and privacy liability, and professional liability).

Geographic activity centers on Florida and the upper Midwest, with Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP) administering a significant multi-state framework covering Minnesota, Oregon, and other participating jurisdictions. Recent representative solicitations include Seminole County, Florida issuing IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission issuing RFI HHS0017013 (posted April 3, 2026) to gather vendor capability information on direct-to-manufacturer prescription programs; and the Minnesota Department of Administration issuing an RFP through MMCAP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with fixed-price and net-price bidding models, a 3 percent administrative fee, and contract effectiveness July 1, 2026. The cooperative purchasing vehicle and multi-state scope suggest sustained regional demand, though the code itself shows sparse recent direct activity.